Want to see ADIL full AI Analyst Report?
ADIL Stock Chart & Stats
$2.78
$0.10(3.73%)
At close: 4:00 PM EDT
$2.78
$0.10(3.73%)
Day’s Range― - ―
52-Week Range$1.31 - $10.76
Previous CloseN/A
Volume38.05K
Average Volume (3M)102.19K
Market Cap
$16.32M
Enterprise Value$45.46
Total Cash (Recent Filing)$28.71M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Nov 18, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.53
Shares Outstanding2,625,890
10 Day Avg. Volume29,103
30 Day Avg. Volume102,186
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.32
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.50Price Target Upside205.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Pipeline ExpansionThe Azora transaction broadens ADIL beyond alcohol-use-disorder treatment into inflammatory bowel disease and provides financing for early clinical milestones. This creates a more diversified pipeline and potentially extends development capacity over the next several quarters.
Precision-medicine PlatformADIL’s precision-medicine strategy seeks to identify patients most likely to respond to AD04, which could improve trial efficiency and clinical differentiation. A validated biomarker-led approach may support a stronger commercial position than an untargeted therapy.
Minimal Debt BurdenMinimal debt limits interest expense, refinancing pressure, and creditor claims while the company remains in clinical development. Although liquidity and equity remain concerns, the absence of significant borrowing provides more flexibility than a highly leveraged balance sheet.
Bears Say
Pre-revenue Development StageADIL has not yet demonstrated commercial revenue, leaving its financial outlook dependent on clinical progress, financing, and eventual regulatory success. The sharp increase in losses indicates substantial spending without corresponding operating income or near-term earnings support.
Negative Equity And Cash BurnPersistent cash consumption means ADIL is not self-funding and will likely require additional capital to advance its programs. Deeply negative equity further reduces financial resilience, increases dependence on financing markets, and may constrain strategic execution.
Nasdaq Listing Compliance RiskFailure to restore required equity or obtain an accepted remediation plan could lead to suspension or delisting. That outcome would reduce trading liquidity, complicate future capital raising, and increase the operational and governance burden during clinical development.
Adial Pharmaceuticals News
ADIL FAQ
What was Adial Pharma’s price range in the past 12 months?
Adial Pharma lowest stock price was $1.31 and its highest was $10.76 in the past 12 months.
What is Adial Pharma’s market cap?
Adial Pharma’s market cap is $16.32M.
When is Adial Pharma’s upcoming earnings report date?
Adial Pharma’s upcoming earnings report date is Nov 18, 2026 which is in 85 days.
How were Adial Pharma’s earnings last quarter?
Adial Pharma released its earnings results on Aug 17, 2026. The company reported -$11.25 earnings per share for the quarter, missing the consensus estimate of -$1.032 by -$10.218.
Is Adial Pharma overvalued?
According to Wall Street analysts Adial Pharma’s price is currently Undervalued.
Does Adial Pharma pay dividends?
Adial Pharma does not currently pay dividends.
What is Adial Pharma’s EPS estimate?
Adial Pharma’s EPS estimate is -0.18.
How many shares outstanding does Adial Pharma have?
Adial Pharma has 2,625,890 shares outstanding.
What happened to Adial Pharma’s price movement after its last earnings report?
Adial Pharma reported an EPS of -$11.25 in its last earnings report, missing expectations of -$1.032. Following the earnings report the stock price went up 25.377%.
Which hedge fund is a major shareholder of Adial Pharma?
Currently, no hedge funds are holding shares in ADIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adial Pharma
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
ADIL Stock 12 Month Forecast
Average Price Target
$8.50
▲(205.76% Upside)
Technical Analysis
Galmed Pharmaceuticals
―
Kiora Pharmaceuticals
―
Matinas BioPharma
―
Alzamend Neuro
―
Calidi Biotherapeutics
―
Ownership Overview
30.11% Insiders
0.24% Mutual Funds
28.84% Other Institutional Investors
40.59% Public Companies and
Individual Investors